Compare GORO & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | SLN |
|---|---|---|
| Founded | 1998 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.0M | 236.2M |
| IPO Year | 2010 | N/A |
| Metric | GORO | SLN |
|---|---|---|
| Price | $1.43 | $7.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.63 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 1.8M | 425.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,759,000.00 | N/A |
| Revenue This Year | $25.99 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 51.78 | N/A |
| 52 Week Low | $0.43 | $3.54 |
| 52 Week High | $1.87 | $8.40 |
| Indicator | GORO | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.33 | 53.27 |
| Support Level | $1.27 | $5.88 |
| Resistance Level | $1.49 | $7.21 |
| Average True Range (ATR) | 0.10 | 0.54 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 19.74 | 49.42 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.